AU2018210397B2 - Combinations of cabozantinib and atezolizumab to treat cancer - Google Patents

Combinations of cabozantinib and atezolizumab to treat cancer Download PDF

Info

Publication number
AU2018210397B2
AU2018210397B2 AU2018210397A AU2018210397A AU2018210397B2 AU 2018210397 B2 AU2018210397 B2 AU 2018210397B2 AU 2018210397 A AU2018210397 A AU 2018210397A AU 2018210397 A AU2018210397 A AU 2018210397A AU 2018210397 B2 AU2018210397 B2 AU 2018210397B2
Authority
AU
Australia
Prior art keywords
subjects
cabozantinib
atezolizumab
dose
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018210397A
Other languages
English (en)
Other versions
AU2018210397A1 (en
Inventor
Colin Hessel
Christian SCHEFFOLD
Gisela Schwab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2018210397A1 publication Critical patent/AU2018210397A1/en
Application granted granted Critical
Publication of AU2018210397B2 publication Critical patent/AU2018210397B2/en
Priority to AU2024203472A priority Critical patent/AU2024203472A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2018210397A 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer Active AU2018210397B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203472A AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US62/448,869 2017-01-20
US201762458447P 2017-02-13 2017-02-13
US62/458,447 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203472A Division AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Publications (2)

Publication Number Publication Date
AU2018210397A1 AU2018210397A1 (en) 2019-07-25
AU2018210397B2 true AU2018210397B2 (en) 2024-02-29

Family

ID=61569414

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018210397A Active AU2018210397B2 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer
AU2024203472A Pending AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203472A Pending AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Country Status (15)

Country Link
US (2) US11198731B2 (enExample)
EP (1) EP3570840B1 (enExample)
JP (3) JP7222895B2 (enExample)
KR (2) KR102610764B1 (enExample)
CN (4) CN110352057A (enExample)
AU (2) AU2018210397B2 (enExample)
BR (1) BR112019015011A2 (enExample)
CA (1) CA3049452A1 (enExample)
ES (1) ES3031468T3 (enExample)
IL (1) IL268138B (enExample)
MA (1) MA47310A (enExample)
MX (2) MX389966B (enExample)
UA (1) UA126970C2 (enExample)
WO (1) WO2018136796A1 (enExample)
ZA (1) ZA201904652B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136796A1 (en) * 2017-01-20 2018-07-26 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20230301979A1 (en) * 2020-07-31 2023-09-28 Exelixis, Inc. Combinations for the treatment of cancer
US20230314440A1 (en) * 2020-08-21 2023-10-05 Exelixis, Inc. Method of treating cancer
EP4308243A4 (en) * 2021-03-19 2025-02-26 Merck Sharp & Dohme LLC METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083414A1 (en) * 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2015123639A1 (en) * 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2017184597A1 (en) * 2016-04-19 2017-10-26 Exelixis, Inc. Triple negative breast cancer treatment method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2018136796A1 (en) * 2017-01-20 2018-07-26 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083414A1 (en) * 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2015123639A1 (en) * 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2017184597A1 (en) * 2016-04-19 2017-10-26 Exelixis, Inc. Triple negative breast cancer treatment method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kwilas, A.R., Ardiani, A., Donahue, R.N. et al. Dual effects of cabozantinib on immune-mediated killing of tumor cells and immune tumor permissiveness. J Transl Med 12, 294 (2014). https://doi.org/10.1186/s12967-014-0294-y *
Powles T et al, Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial CarcinomaEUR Urol Suppl 2017; 16(10);e2789 *

Also Published As

Publication number Publication date
MX389966B (es) 2025-03-20
CN117771363A (zh) 2024-03-29
WO2018136796A1 (en) 2018-07-26
CN117205313A (zh) 2023-12-12
MX2022001718A (es) 2022-03-11
KR20190107103A (ko) 2019-09-18
ES3031468T3 (en) 2025-07-09
US20190352403A1 (en) 2019-11-21
JP7222895B2 (ja) 2023-02-15
US20220056138A1 (en) 2022-02-24
BR112019015011A2 (pt) 2020-04-28
MA47310A (fr) 2019-11-27
KR102610764B1 (ko) 2023-12-07
JP2024019720A (ja) 2024-02-09
IL268138A (en) 2019-09-26
AU2024203472A1 (en) 2024-06-13
MX2019008032A (es) 2019-12-16
ZA201904652B (en) 2024-11-27
CA3049452A1 (en) 2018-07-26
UA126970C2 (uk) 2023-03-01
CN110352057A (zh) 2019-10-18
KR20230169458A (ko) 2023-12-15
AU2018210397A1 (en) 2019-07-25
US11198731B2 (en) 2021-12-14
NZ755494A (en) 2025-06-27
JP2022121594A (ja) 2022-08-19
CN117205312A (zh) 2023-12-12
IL268138B (en) 2022-08-01
EP3570840B1 (en) 2025-03-19
EP3570840A1 (en) 2019-11-27
JP2020514311A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
AU2018210397B2 (en) Combinations of cabozantinib and atezolizumab to treat cancer
CN110536684A (zh) 三联组合制剂以及治疗心血管疾病或降低心血管疾病风险的方法
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
Nishiyama et al. Sarcopenia may influence the prognosis in advanced thyroid cancer patients treated with molecular targeted therapy
TW202440113A (zh) 治療早期乳癌之方法
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Ciardiello et al. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Zhang et al. Efficacy and safety of HIPEC combined with PD-1 and SOX chemotherapy for gastric or oesophagogastric junctional cancer with peritoneal metastasis (HISTORIA): protocol for a prospective, multicentre, single-arm, phase II study
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
Emadi Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Carthon Winship Protocol#: Winship4643-19 TITLE: A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
DEVELOPM Drug DeveloPment
Wei A Phase II, Single-center, Single-arm Clinical Trial on the Efficacy and Safety of Anti-PD-1 antibody (IBI308) Combined with Anlotinib for the Treatment of Recurrent or Advanced Endometrial Cancer
Niemann et al. EUDRACT NUMBER: Clinicaltrials. gov number
Person Study protocol
Awan Highlights in Chronic Lymphocytic Leukemia From the 2022 American Society of Clinical Oncology Annual
Li Protocol Abstract
TEAM CLINICAL PROTOCOL

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)